keyword
MENU ▼
Read by QxMD icon Read
search

pancreatic tumours

keyword
https://www.readbyqxmd.com/read/28819950/successful-eus-guided-ethanol-ablation-of-insulinoma-four-year-follow-up-case-report-and-literature-review
#1
Krzysztof Dąbkowski, Paula Gajewska, Kamila Walter, Magdalena Londzin-Olesik, Andrzej Białek, Elżbieta Andrysiak-Mammos, Beata Kos-Kudła, Teresa Starzyńska
INTRODUCTION: EUS-guided ethanol ablation of insulinoma is a new method of treatment of this neuroendocrine tumour. Ablation is recommended in patients who are poor surgical candidates or refuse surgery. We present a case of an 81-year-old female with symptomatic insulinoma, treated successfully with EUS-guided alcoholic ablation, along with a literature review including 28 other previously described cases. The effectiveness, safety of the therapy, and technical procedure-related issues are summarised...
2017: Endokrynologia Polska
https://www.readbyqxmd.com/read/28811077/the-receptor-for-advanced-glycation-end-products-a-fuel-to-pancreatic-cancer
#2
REVIEW
Uzma Shahab, Mohd Kaleem Ahmad, Abbas Ali Mahdi, Mohd Waseem, Binish Arif, Moinuddin, Saheem Ahmad
The receptor for advanced glycation end products (RAGEs) was first illustrated in the year 1992. RAGE is a single-transmembrane and multi-ligand component of the immunoglobulin protein super family. The engagement of RAGE turns out to an establishment of numerous intracellular signalling mechanisms resulting in the progression and perpetuation of many types of cancer including, the pancreatic cancer. The present review primarily focuses on the multi-ligand activation of RAGEs leading to the downstream signalling cascade activation...
August 12, 2017: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/28809096/pancreatico-jejunostomy-decreases-post-operative-pancreatic-fistula-incidence-and-severity-after-central-pancreatectomy
#3
Frédéric Borel, Mehdi Ouaissi, Aude Merdrignac, Aurelien Venara, Valéria De Franco, Laurent Sulpice, Antoine Hamy, Nicolas Regenet
BACKGROUNDS: Central pancreatectomy (CP) is an alternative to pancreaticoduodenectomy and distal pancreatectomy in benign tumours of pancreatic isthmus management. It is known for a high post-operative pancreatic fistula (POPF) rate. The purpose of this study was to compare POPF incidence between pancreatico-jejunostomy (PJ) and pancreatico-gastrostomy (PG). METHODS: Fifty-eight patients (mean age 53.9 ± 1.9 years) who underwent a CP in four French University Hospitals from 1988 to 2011 were analysed...
August 15, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28808290/molecular-mr-imaging-of-fibrosis-in-a-mouse-model-of-pancreatic-cancer
#4
Miloslav Polasek, Yan Yang, Daniel T Schühle, Mohammad A Yaseen, Young R Kim, Yu Sub Sung, Alexander R Guimaraes, Peter Caravan
Fibrosis with excessive amounts of type I collagen is a hallmark of many solid tumours, and fibrosis is a promising target in cancer therapy, but tools for its non-invasive quantification are missing. Here we used magnetic resonance imaging with a gadolinium-based probe targeted to type I collagen (EP-3533) to image and quantify fibrosis in pancreatic ductal adenocarcinoma. An orthotopic syngeneic mouse model resulted in tumours with 2.3-fold higher collagen level compared to healthy pancreas. Animals were scanned at 4...
August 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28803454/serum-carbohydrate-antigen-19-9-in-pancreatic-adenocarcinoma-a-mini-review-for-surgeons
#5
REVIEW
Su Kah Goh, Grace Gold, Christopher Christophi, Vijayaragavan Muralidharan
The optimal management of oncological conditions is reflected by the careful interpretation of investigations for screening, diagnosis, staging, prognostication and surveillance. Serum tumour markers are examples of commonly requested tests in conjunction with other imaging and endoscopic tests that are used to help clinicians to stratify therapeutic decisions. Serum carbohydrate antigen 19-9 (CA19-9) is a key biomarker for pancreatic cancers. Although this biomarker is considered clinically useful and informative, clinicians are often challenged by the accurate interpretation of elevated serum CA19-9 levels...
August 13, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28802189/pt-but-not-pn-stage-of-the-8th-tnm-classification-significantly-improves-prognostication-in-pancreatic-ductal-adenocarcinoma
#6
Anna Melissa Schlitter, Moritz Jesinghaus, Carsten Jäger, Björn Konukiewitz, Alexander Muckenhuber, Ihsan Ekin Demir, Marcus Bahra, Carsten Denkert, Helmut Friess, Günter Kloeppel, Güralp O Ceyhan, Wilko Weichert
The UICC TNM (tumour-node-metastasis) staging system for pancreatic ductal adenocarcinoma (PDAC) has been a matter of debate over decades because survival prediction based on T stages was weak and unreliable. To improve staging, the recently published 8th TNM edition (2016) introduced a conceptually completely changed strictly size-based T staging system and a refined N stage for PDAC. To investigate the clinical value of the novel TNM classification, we compared the prognostic impact of pT and pN stage between the 7th and 8th edition in two well-characterised independent German PDAC cohorts from different decades, including a total number of 523 patients...
August 9, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28798308/prognostic-value-of-programmed-cell-death-protein-1-expression-on-cd8-t-lymphocytes-in-pancreatic-cancer
#7
Tao Shen, Liangjing Zhou, Hua Shen, Chengfei Shi, Shengnan Jia, Guo Ping Ding, Liping Cao
Pancreatic cancer is one of the most aggressive malignancies and has a highly immunosuppressive tumour microenvironment. Immune checkpoint blockade has led to remarkable and durable objective responses in a number of malignancies and antibody-based strategies targeting programmed cell death protein 1 (PD-1) are showing promise where traditional modalities of surgery, radiotherapy, and chemotherapy have failed. In this study, we examined the clinical value of PD-1 protein expression by CD8+ peripheral T lymphocytes or tumour-infiltrating T lymphocytes (TILs) in pancreatic ductal adenocarcinoma (PDAC)...
August 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28791195/nanoplasmonic-quantification-of-tumor-derived-extracellular-vesicles-in-plasma-microsamples-for-diagnosis-and-treatment-monitoring
#8
Kai Liang, Fei Liu, Jia Fan, Dali Sun, Chang Liu, Christopher J Lyon, David W Bernard, Yan Li, Kenji Yokoi, Matthew H Katz, Eugene J Koay, Zhen Zhao, Ye Hu
Tumour-derived extracellular vesicles (EVs) are of increasing interest as a resource of diagnostic biomarkers. However, most EV assays require large samples, are time-consuming, low-throughput and costly, and thus impractical for clinical use. Here, we describe a rapid, ultrasensitive and inexpensive nanoplasmon-enhanced scattering (nPES) assay that directly quantifies tumor-derived EVs from as little as 1 μL of plasma. The assay uses the binding of antibody-conjugated gold nanospheres and nanorods to EVs captured by EV-specific antibodies on a sensor chip to produce a local plasmon effect that enhances tumour-derived EV detection sensitivity and specificity...
2017: Nature biomedical engineering
https://www.readbyqxmd.com/read/28789903/patients-with-resected-histologically-re-confirmed-pancreatic-ductal-adenocarcinoma-pdac-can-achieve-long-term-survival-despite-t3-tumour-or-nodal-involvement-the-finnish-register-study-2000-2013
#9
Reea Ahola, Antti Siiki, Kaija Vasama, Martine Vornanen, Juhani Sand, Johanna Laukkarinen
BACKGROUND: Long-term survival of patients with operated pancreatic ductal adenocarcinoma (PDAC) has been associated with resection status, disease stage and centralisation. However, no previous reports are available about long-term survivors of PDAC with confirmed histology covering an entire nation. Our aim was to analyze retrospectively confirmed long-term survivors of PDAC operated on in Finland 2000-2008. METHOD: PDAC patients operated between 2000 and 2008 were selected from Finnish patient registers and archives...
July 29, 2017: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/28782798/pancreatoduodenectomy-with-portal-vein-resection-for-distal-cholangiocarcinoma
#10
T Maeta, T Ebata, E Hayashi, T Kawahara, S Mizuno, N Matsumoto, S Ohta, M Nagino
BACKGROUND: Little is known about the value of portal vein (PV) resection in distal cholangiocarcinoma. The aim of this study was to evaluate the clinical significance of PV resection in distal cholangiocarcinoma. METHODS: Patients who underwent pancreatoduodenectomy (PD) for distal cholangiocarcinoma between 2001 and 2010 at one of 31 hospitals in Japan were reviewed retrospectively with special attention to PV resection. Short- and long-term outcomes were evaluated...
August 7, 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28782747/laparoscopic-surgery-for-solitary-insulinoma-in-the-absence-of-ious
#11
Abhay Narendra Dalvi, Mahadeo Namdeo Garale, Yogesh Prabhakar Takalkar, Sameer Ashok Rege, Pinky Manoharlal Thapar, Lila Anurag, Nalini Samir Shah
BACKGROUND: Insulinomas are the most common pancreatic neuroendocrine neoplasms. In spite of adequate pre-operative localisation, conventional surgical methods rely on intraoperative palpation. Intraoperative ultrasonography (IOUS) is said to aid in accurate localisation, decreases morbidity. Laparoscopic removal of pancreatic endocrine neoplasms is beneficial due to magnification and minimal invasion; however, in the absence of IOUS, error of judgement may lead to conversion to open surgery, thereby relying on 'palpation method' to localise the tumour...
August 1, 2017: Journal of Minimal Access Surgery
https://www.readbyqxmd.com/read/28782321/insulinoma-presenting-with-neuropsychiatric-symptoms
#12
S Aggarwal, N Nand, N Damle, R Godara, R Kumar
An insulinoma is a rare pancreatic endocrine tumor which is typically a hypervascular, solitary small tumour. 90 % of tumors are benign and less than 2 cm in size. Some insulinomas are associated with MEN-1 syndrome. Some cases of insulinoma may present with neuropsychiatric symptoms and may be wrongly diagnosed as psychosis. We report a case of insulinoma in a 55 years old female who presented with episodes of abnormal behavior and altered sensorium. On detailed investigations she was diagnosed as a case of hyperinsulinemic hypoglycemia due to insulinoma (in her case MRI abdomen was normal) DOTANOC PET CT confirmed the insulinoma in body/tail of pancreas...
June 2017: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/28774899/89zr-anti-%C3%AE-h2ax-tat-but-not-18f-fdg-allows-early-monitoring-of-response-to-chemotherapy-in-a-mouse-model-of-pancreatic-ductal-adenocarcinoma
#13
James C Knight, Michael J Mosley, Luisa Contreras Bravo, Veerle Kersemans, Philip D Allen, Somnath Mukherjee, Eric O'Neill, Bart Cornelissen
Purpose: Late-stage, unresectable pancreatic ductal adenocarcinoma (PDAC) is largely resistant to chemotherapy and consequently has a very poor 5-year survival rate of < 5%. The ability to assess the efficacy of a treatment soon after its initiation would enable rapid switching to potentially more effective therapies if the current treatment is found to be futile. We have evaluated the ability of the PET imaging agent, (89)Zr-anti-γH2AX-TAT, to monitor DNA damage in response to fluouracil (5-FU), gemcitabine, or capecitabine treatment in a mouse model of pancreatic cancer...
August 3, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28772284/diagnostic-value-of-ca19-9-circulating-tumour-dna-and-circulating-tumour-cells-in-patients-with-solid-pancreatic-tumours
#14
David Sefrioui, France Blanchard, Emmanuel Toure, Paul Basile, Ludivine Beaussire, Claire Dolfus, Anne Perdrix, Marianne Paresy, Michel Antonietti, Isabelle Iwanicki-Caron, Raied Alhameedi, Stephane Lecleire, Alice Gangloff, Lilian Schwarz, Florian Clatot, Jean-Jacques Tuech, Thierry Frébourg, Fabrice Jardin, Jean-Christophe Sabourin, Nasrin Sarafan-Vasseur, Pierre Michel, Frédéric Di Fiore
BACKGROUND: The direct comparison of CA19.9, circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has never been performed for the diagnosis of solid pancreatic tumours (SPTs). METHODS: We included 68 patients with a SPT referred for EUS-FNA. CTCs were analysed using size-based platform and ctDNA using digital PCR. The sensitivity, specificity, negative and positive predictive values were evaluated for each marker and their combination...
August 3, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28772128/cytotoxic-tumour-infiltrating-t-lymphocytes-influence-outcome-in-resected-pancreatic-ductal-adenocarcinoma
#15
Philipp Lohneis, Marianne Sinn, Sven Bischoff, Anja Jühling, Uwe Pelzer, Lilianna Wislocka, Marcus Bahra, Bruno V Sinn, Carsten Denkert, Helmut Oettle, Hendrik Bläker, Hanno Riess, Korinna Jöhrens, Jana K Striefler
BACKGROUND: We studied the prognostic effect of CD3-, CD8- and CD103-positive T lymphocytes in a cohort of 165 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the treatment group (adjuvant gemcitabine) and the untreated control group of the CONKO-001 study. METHODS: Immunohistochemical stainings on tissue microarrays (TMAs) against CD3, CD8 and CD103 were performed according to standard procedures. RESULTS: A high number of CD8-positive lymphocytes were significantly and independently associated with longer disease-free survival (DFS) and overall survival (OS) in the overall study population...
July 31, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28770102/a-predictive-analysis-of-the-sp120-and-10d7g2-antibodies-for-human-equilibrative-nucleoside-transporter-1-hent1-in-pancreatic-ductal-adenocarcinoma-treated-with-adjuvant-gemcitabine
#16
Steve E Kalloger, Maziar Riazy, Basile Tessier-Cloutier, Joanna M Karasinska, Dongxia Gao, Renata D Peixoto, Setareh Samimi, Christine Chow, Hui-Li Wong, John R Mackey, Daniel J Renouf, David F Schaeffer
Expression of human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma (PDAC) has been postulated to be a marker of sensitivity to gemcitabine. However, heterogeneity in the studies attempting to quantify hENT1 expression in patients with PDAC treated with gemcitabine has yielded inconclusive results that impede the adoption of hENT1 expression as a predictive biomarker. Tissue microarrays consisting of PDAC specimens from 227 patients acquired between 1987 and 2013 annotated with treatment and outcome information were subjected to staining with two antibodies for hENT1 (10D7G2 and SP120) on a single automated platform and scored by two independent pathologists blinded to treatment and outcome...
July 2017: Journal of Pathology. Clinical Research
https://www.readbyqxmd.com/read/28768698/the-future-advances-in-therapeutic-approach-and-management-strategies-for-men1
#17
Rachel S van Leeuwaarde, Joanne M de Laat, Carolina R C Pieterman, Koen M A Dreijerink, Menno Vriens, Gerlof D Valk
Multiple endocrine neoplasia type 1 is a rare autosomal inherited disorder associated with a high risk for patients to simultaneously develop tumours of the parathyroid glands, duodeno-pancreatic neuroendocrine tumors and tumors of the anterior pituitary gland. Early identification of MEN1 in patients enables presymptomatic screening of manifestations which makes timely interventions possible with the intention to prevent morbidity and mortality. Causes of death nowadays have shifted towards local or metastatic progression of malignant neuro endocrine tumors...
August 2, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28765698/early-radiological-assessment-of-locally-advanced-pancreatic-cancer-treated-with-electrochemotherapy
#18
Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Mauro Piccirillo, Maddalena Leongito, Raffaele Palaia, Francesco Granata, Secondo Lastoria, Francesco Izzo, Antonella Petrillo
AIM: To report early imaging assessment of ablated area post electrochemotherapy (ECT) in patients with locally advanced pancreatic cancer (LAPC). METHODS: ECT was performed in 19 LAPC patients enrolled in an approved ongoing clinical phase I/II study. Before and after ECT, 18 patients underwent computed tomography (CT) scan, 11 patients underwent morphological and functional magnetic resonance (MR) scan (dynamic contrast enhanced-MRI) calculating wash-in slope (WIS) and wash-out slope (WOS); diffusion weighted imaging calculating pseudo-diffusivity (Dp), perfusion fraction (fp) and tissue diffusivity (Dt); 10 patients underwent positron emission tomography (PET)...
July 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28764995/magnetically-responsive-microbubbles-as-delivery-vehicles-for-targeted-sonodynamic-and-antimetabolite-therapy-of-pancreatic-cancer
#19
Yingjie Sheng, Estelle Beguin, Heather Nesbitt, Sukanta Kamila, Joshua Owen, Lester C Barnsley, Bridgeen Callan, Christopher O'Kane, Nikolitsa Nomikou, Rifat Hamoudi, Mark A Taylor, Mark Love, Paul Kelly, Declan O'Rourke, Eleanor Stride, Anthony P McHale, John F Callan
Magnetically responsive microbubbles (MagMBs), consisting of an oxygen gas core and a phospholipid coating functionalised with Rose Bengal (RB) and/or 5-fluorouracil (5-FU), were assessed as a delivery vehicle for the targeted treatment of pancreatic cancer using combined antimetabolite and sonodynamic therapy (SDT). MagMBs delivering the combined 5-FU/SDT treatment produced a reduction in cell viability of over 50% when tested against a panel of four pancreatic cancer cell lines in vitro. Intravenous administration of the MagMBs to mice bearing orthotopic human xenograft BxPC-3 tumours yielded a 48...
July 29, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28761758/the-european-society-for-medical-oncology-magnitude-of-clinical-benefit-scale-field-tested-in-infrequent-tumour-entities-an-extended-analysis-of-its-feasibility-at-the-medical-university-of-vienna
#20
Barbara Kiesewetter, Markus Raderer, Gerald W Prager, Thorsten Fuereder, Christine Marosi, Matthias Preusser, Michael Krainer, Gottfried J Locker, Thomas Brodowicz, Christoph C Zielinski
BACKGROUND: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a new tool to quantify the clinical benefit that may be anticipated from a novel anticancer treatment. We present here an analysis on the feasibility of the ESMO-MCBS in less frequent tumour entities. METHODS: This study evaluates the practicability of the ESMO-MCBS for metastatic neuroendocrine tumours (NETs), soft tissue sarcomas, glioblastoma, thyroid cancer, pancreatic cancer, head/neck cancer, urothelial cancer and ovarian cancer at the Medical University Vienna...
2017: ESMO Open
keyword
keyword
100734
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"